Phathom Pharmaceuticals/$PHAT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Ticker
$PHAT
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
427
ISIN
US71722W1071
Website
PHAT Metrics
BasicAdvanced
$759M
-
-$5.19
0.15
-
Price and volume
Market cap
$759M
Beta
0.15
52-week high
$18.68
52-week low
$2.21
Average daily volume
4.1M
Financial strength
Current ratio
3.578
Quick ratio
3.359
Long term debt to equity
-161.67
Total debt to equity
-166.866
Interest coverage (TTM)
-3.93%
Profitability
EBITDA (TTM)
-285.618
Gross margin (TTM)
86.23%
Net profit margin (TTM)
-422.42%
Operating margin (TTM)
-349.84%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-55.01%
Return on equity (TTM)
142.04%
Valuation
Price to revenue (TTM)
8.865
Price to book
-2.24
Price to tangible book (TTM)
-2.24
Price to free cash flow (TTM)
-2.566
Free cash flow yield (TTM)
-38.97%
Free cash flow per share (TTM)
-424.77%
Growth
Revenue change (TTM)
3,055.71%
Earnings per share change (TTM)
16.45%
3-year earnings per share growth (CAGR)
9.11%
What the Analysts think about PHAT
Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.
Bulls say / Bears say
Phathom Pharmaceuticals' product, VOQUEZNA, has achieved over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers, indicating strong market adoption. (GlobeNewswire)
The company reported net revenues of $28.5 million for Q1 2025, surpassing consensus estimates and demonstrating robust financial performance. (Zacks)
Analysts maintain a 'Strong Buy' consensus rating with a 12-month average price target of $17.80, suggesting significant upside potential from current levels. (StockAnalysis)
Phathom Pharmaceuticals' stock has declined approximately 47.2% since the beginning of the year, indicating potential investor concerns. (Zacks)
The company reported a quarterly loss of $1.07 per share in Q1 2025, slightly missing the consensus estimate and highlighting ongoing profitability challenges. (Zacks)
Uncertainty surrounding patent exclusivity for VOQUEZNA poses a substantial risk to future revenue, as evidenced by the company's filing of a Citizen's Petition to secure a 10-year exclusivity period. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
PHAT Financial Performance
Revenues and expenses
PHAT Earnings Performance
Company profitability
PHAT News
AllArticlesVideos
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
GlobeNewsWire·4 days ago
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
GlobeNewsWire·2 weeks ago
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Phathom Pharmaceuticals stock?
Phathom Pharmaceuticals (PHAT) has a market cap of $759M as of June 20, 2025.
What is the P/E ratio for Phathom Pharmaceuticals stock?
The price to earnings (P/E) ratio for Phathom Pharmaceuticals (PHAT) stock is 0 as of June 20, 2025.
Does Phathom Pharmaceuticals stock pay dividends?
No, Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Phathom Pharmaceuticals dividend payment date?
Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders.
What is the beta indicator for Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.